[HTML][HTML] Trastuzumab Deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY …
C Saura, S Modi, I Krop, YH Park, SB Kim, K Tamura… - Annals of …, 2024 - Elsevier
Background Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-
Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with …
Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with …
[HTML][HTML] Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY …
C Saura, S Modi, I Krop, YH Park, SB Kim… - Annals of …, 2024 - annalsofoncology.org
Background Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-
Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with …
Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with …
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
C Saura, S Modi, I Krop, YH Park… - Annals of oncology …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-
Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with …
Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with …
Trastuzumab Deruxtecan in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer: Updated Survival Results From a Phase 2 Trial (DESTINY …
C Saura, S Modi, I Krop, YH Park, SB Kim… - Annals of Oncology …, 2023 - europepmc.org
Background Primary analysis of the multicenter, open-label, single-arm, phase 2 DESTINY-
Breast01 trial (median follow-up, 11.1 months) demonstrated durable antitumor activity with …
Breast01 trial (median follow-up, 11.1 months) demonstrated durable antitumor activity with …